Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery

Inclusion Criteria: * Provide written informed consent prior to the initiation of study procedures * Are \> 18 years of age * Women consented to undergo standard of care minimally invasive pelvic surgery (traditional laparoscopy and robotic surgery) * Women who are expected to be admitted to the hospital following surgery for at least 24 hours Exclusion Criteria: * Are unwilling or unable to provide informed consent. * Are unwilling or unable to comply with the requirements of the protocol. * History of prior urologic surgery. * History of prior pelvic surgery. * History of known retroperitoneal fibrosis. * Have any of the following screening laboratory values: * Hemoglobin ≤ 8.0 g/dL; * Absolute neutrophil count (ANC) ≤ 1500/μL; * Platelet count ≤ 100,000/μL; * Serum creatinine ≥ 1.5 x the institutional upper limit of normal (IULN) creatinine; * Serum bilirubin ≥ 1.5 x IULN; * Aspartate transaminase (AST or serum glutamic oxaloacetic transaminase, SGOT) ≥ 2x IULN;• Alanine transaminase (ALT or serum glutamate pyruvate transaminase, SGPT) ≥ 2 x IULN. * Females who are pregnant, lactating, or breastfeeding; * Any other condition that, in the Investigator's judgment, would potentially compromise the study compliance or the ability to evaluate safety or efficacy.